| GRECC | Geriatric Research and Education Clinical Center |
|---|---|
| ICD | I-cell disease; immune complex disease; implantable cardioverter defibrillator; impulse-control diso... |
| ERF | Education and Research Foundation; external rotation in flexion; Eye Research Foundation |
| ISR | information storage and retrieval; Institute for Sex Research; Institute of Surgical Research; insul... |
| CAS | calcarine sulcus; calcific aortic stenosis; Cancer Attitude Survey; carbohydrate-active steroid; car... |
| normal occlusion | That arrangement of teeth and their supporting structure which is usually found in health and which approaches an ideal or standard arrangement. Synonym: normal bite. Synonym: neutral occlusion. (05 Mar 2000) |
|---|---|
| normal opsonin | That normally present in the blood, i.e., without stimulation by a known, specific antigen such as certain complement components; it is relatively thermolabile and reacts with various organisms. Synonym: common opsonin, thermolabile opsonin. Specific opsonin, antibodies formed in response to stimulation by a specific antigen, either as a result of an attack of a disease, or injections with a suitably prepared suspension of the specific microorganism. Synonym: immune opsonin, thermostable opsonin. (05 Mar 2000) |
| normal pressure hydrocephalus | <neurology> A brain disorder caused by blockage of the flow of cerebrospinal fluid (CSF), with enlargement of the ventricles of the brain (keep the pressure normal) and compression of brain tissue. Brain atrophy is the result. In this condition the CSF is produced normally but not reabsorbed. Symptom onset is gradual. A key feature is dementia. Treatment is surgical (VP shunt). (13 Nov 1997) |
| normal range | Normal results can fall outside the normal range. By convention, the normal range is set to cover ninety-five percent (95%) of values from a normal population. Five percent (5%) of normal results therefore fall outside the normal range. (12 Dec 1998) |
| normal serum | A nonimmune serum, usually with reference to a serum obtained prior to immunization. (05 Mar 2000) |
| normal tartrate | Tartrate that contains no uncombined acid groups. (05 Mar 2000) |
| normal toxin | A toxin solution holding exactly 100 lethal doses in 1 ml. (05 Mar 2000) |
| normal values | A set of laboratory test value's used to characterise apparently healthy individuals; now replaced by reference value's. (05 Mar 2000) |
| Addison's clinical planes | A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison. (05 Mar 2000) |
| pathology, clinical | A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids. (12 Dec 1998) |
| chemistry, clinical | The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy. (12 Dec 1998) |
| pharmacology, clinical | The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans. (12 Dec 1998) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |